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ABSTRACT 
We previously reported non-aqueous silicone elastomer gels (SEGs) for sustained vaginal 
administration of the CCR5-targeted entry inhibitor maraviroc. Here, we describe chemically 
modified SEGs (h-SEGs) in which the hydrophobic cyclomethicone component was partially 
replaced with relatively hydrophilic silanol-terminated polydimethylsiloxanes (st-PDMS). 
Maraviroc and emtricitabine (a nucleoside reverse transcriptase inhibitor), both currently under 
evaluation as topical microbicides to counter sexual transmission of human immunodeficiency 
virus type 1 (HIV-1), were used as model antiretroviral (ARV) drugs. Gel viscosity and in vitro 
ARV release were significantly influenced by st-PDMS molecular weight and concentration in 
the h-SEGs. Unexpectedly, gels prepared with lower molecular weight grades of st-PDMS 
showed higher viscosities. h-SEGs provided enhanced release over 24 h compared with aqueous 
hydroxyethylcellulose (HEC) gels, did not modify the pH of simulated vaginal fluid (SVF), and 
were shown to less cytotoxic than standard hydroxyethylcellulose (HEC) vaginal gel. ARV 
solubility increased as st-PDMS molecular weight decreased (i.e. as percentage hydroxyl content 
increased), helping to explain the in vitro release trends. Dye ingression and SVF dilution studies 
confirmed the increased hydrophilicity of the h-SEGs. h-SEGS have potential for use in vaginal 
drug delivery, particularly for ARV-based HIV-1 microbicides. 
 
Abstract word count: 200  
ABBREVIATIONS  
ARV – antiretroviral 
FTC - emtricitabine 
HEC - hydroxyethylcellulose 
HIV – human immunodeficiency virus  
IPA – isopropyl alcohol 
h-SEG – hydrophilically modified silicone elastomer gel 
PDMS – polydimethylsiloxane 
PrEP – pre-exposure prophylaxis 
MVC - maraviroc 
SEG – silicone elastomer gel 
st-PDMS – silanol-terminated polydimethylsiloxane  
SVF – simulated vaginal fluid 
TFA – trifluoroacetic acid
1. INTRODUCTION 
Biomedical strategies for HIV prevention have focused primarily on three different strategies: 
vaccines, vaginal microbicides and oral pre-exposure prophylaxis (PrEP). Despite determined 
efforts over almost thirty years, a HIV vaccine remains as elusive as ever. The two most recent 
efficacy trials of HIV vaccine candidates (the STEP and HVTN 505 studies) were stopped early 
due to initial results indicating that they were ineffective in preventing HIV infections.1,2 As a 
relatively recent HIV prevention method, PrEP holds out greater promise of success, but will 
require strict adherence to prescribed daily regimens in order to be effective. In July 2012 the 
U.S. Food and Drug Administration approved the combination medication tenofovir disoproxil 
fumarate plus emtricitabine (TDF/FTC) for use as PrEP among sexually active adults at risk of 
HIV infection.3-5 
 
The development of vaginally administered products containing antiretroviral (ARV) 
microbicides remains a major goal in HIV prevention.6-9 To date, emphasis has been placed on 
microbicide-loaded aqueous gels, with formulations based predominantly on the well-established 
poly(acrylic acid) (Carbopol®) and hydroxyethylcellulose (HEC) polymers that are widely used 
gelling agents in other vaginal products.10-14 A 1% w/w tenofovir / 2.7% w/w aqueous HEC gel is 
currently the most advanced candidate, with Phase 1 and 2 safety and acceptability studies 
(HPTN 050 and HPTN 059, respectively) successfully completed.15-17 In 2010, the Phase IIb 
CAPRISA 004 trial results showed a 39% reduction (compared to placebo) in the incidence of 
new HIV-1 infections in sexually active women using the tenofovir gel.17 A 54% reduction in 
incidence was found for the sub-group of women who were most adherent to the two-dose, 
coitally dependent BAT24 dosing protocol, underscoring the critical importance of adherence for 
microbicide effectiveness.17 Pericoital dosing schedules, such as the one used in the CAPRISA 
004 trial, can be problematic from the perspective of user adherence with timing and frequency of 
dosing contributing to variability in the level of protection achieved.17,27 Less coitally-dependent 
or coitally-independent strategies are expected to improve microbicide efficacy. While long-
acting ARV-releasing vaginal ring devices are being developed to specifically address these 
adherence issues,18-25 they are generally only suitable for delivery of drugs with very specific 
physicochemical characteristics.26 A vaginal gel applied once-daily and capable of maintaining 
protective local ARV concentrations over a 24 h period may be a satisfactory approach to the 
adherence problem. To this end, a once-daily 1% tenofovir aqueous HEC gel was evaluated as 
part of the VOICE Phase 2B safety and acceptability study (Microbicide Trials Network MTN-
003).27 However, this daily dosing schedule was not shown to reduce rates of HIV acquisition.27 
A recent vaginal challenge study in macaques dosed with a HEC-based gel containing maraviroc, 
a CCR5-targeted HIV-1 entry inhibitor, found that the protection half-life was only 4 h.28 
Therefore, unless there is a strong ligand binding or a tissue depot effect (as observed with 
UC781, a non-nucleoside reverse transcriptase inhibitor microbicide candidate),29,30 a single 
application of a water-based gel may not be capable of sustained vaginal retention and 
maintenance of protective ARV concentrations throughout a full 24 h period. The concept of 
enhancing mucosal retention of vaginal gels in order to sustain local or systemic drug levels is 
well established using mucoadhesive gel systems.31-36 However, given the high water content of 
most commercial vaginal gels and their propensity for dilution in vaginal fluid, it is not surprising 
that retention is generally limited to a few hours.36-40 
 
Non-aqueous silicone gels are already widely and safely used as personal lubricants for vaginal 
and rectal application.41,42 Recently, we demonstrated that vaginal administration of non-aqueous 
silicone elastomer gels (SEGs) in rhesus macaques provided higher and more sustained 
maraviroc concentrations in the vaginal fluid and vaginal tissue compartments compared with 
HEC-based gels, presumably due to their enhanced mucosal retention due to lack of water 
miscibility40 However, as with silicone elastomer vaginal rings, SEGs may be less useful for 
formulation of relatively hydrophilic drugs owing to their limited solubility in the gel matrix and 
giving rise to potentially non-optimal release and pharmacokinetics. SEGs typically comprise an 
elastomeric component (a lightly crosslinked polydimethylsiloxane, PDMS) and a non-aqueous 
low molecular weight dilutant (e.g. cyclomethicone) (Fig. 1). An 80/20 SEG formulation 
(silicone elastomer to cyclomethicone ratio) containing 33 mg/mL w/w maraviroc was previously 
tested in rhesus macaques.40 We hypothesized that the substitution of the cyclomethicone 
component with a linear, low molecular weight, silanol-terminated PDMS (st-PDMS) would 
enhance the relative hydrophilicity of the SEGs (although preferably not to the extent of making 
them aqueous miscible), thereby improving the solubility and release of incorporated hydrophilic 
ARVs. Here, we demonstrate the potential of these hydrophilically-modified SEGs, hereafter 
termed h-SEGs, for sustained release of the model ARV microbicide compounds maraviroc and 
emtricitabine. Both compounds used as part of multi-drug regimens for treating HIV-1-infected 
individuals, are being tested for their potential as orally delivered pre-exposure prophylaxis to 
prevent infection,3,4,43 and may be useful as topically administered vaginal or rectal 
microbicides.16,17,25 
 
2. MATERIALS AND METHODS 
2.1. Materials 
ST-Elastomer 10 and cyclomethicone, used for preparation of the SEGs and h-SEGs, were kindly 
donated by Dow Corning® (Midland, USA). Various st-PDMS compounds (DMS S12, viscosity 
16-32 cST, MW 400-700 Da; DMS S14, viscosity 35-45 cST, MW 700-1500 Da; DMS S15, 
viscosity 45-85 cST, MW 2000-3500 Da; DMS S21, viscosity 90-120 cST, MW 4200 Da; DMS 
S27, viscosity 700-800 cST, MW 18,000 Da; DMS S35, viscosity 5,000 cST, MW 49,000 Da; 
DMS S51, viscosity 90,000-150,000 cST, MW 139,000 Da) were supplied by Fluorochem 
(Hadfield, Derbyshire, UK). Various grades of HEC (Natrosol® 250 HX, Natrosol® 250 M-Pharm 
and Natrosol® 250 HXX) were obtained from Aqualon Hercules (Wilmington, USA), sodium 
chloride from Sigma Aldrich® (St. Louis, MO, USA), potassium chloride and potassium 
dihydrogen orthophosphate from AnalaR® VWR (West Chester, Pennsylvania, USA) and 
disodium hydrogen orthophosphate from Fisher Scientific (Loughborough, Leicestershire, UK). 
Maraviroc and emtricitabine were supplied by ViiV Healthcare (Brentford, Middlesex, UK) and 
CONRAD (Arlington, Virginia, USA), respectively. All other materials and solvents were 
supplied by Sigma Aldrich® and were used as received. Commercial vaginal gels Gynofit® 
(Tentan AG), Replens® (Anglian Pharma), Metrogel® (Galderma), Gygel® (Marlborough 
Pharmaceuticals), Balance Activ® (Kullgren Pharma) and RepHresh® (Anglian Pharma) were 
obtained from AAH Pharmaceuticals (Belfast, UK). 
 
2.2. Preparation of HEC and silicone elastomer gels 
SEGs and h-SEGs were prepared by mixing the required quantities of ST-Elastomer 10, 
cyclomethicone and st-PDMS in a SpeedMixerTM (DAC 150 FVZ-K, Synergy Devices Ltd., UK, 
1 min, 3000 rpm). Aqueous HEC gels were prepared according to the method described 
previously.40   Briefly, HEC was added to phosphate buffered saline with mixing (SpeedMixerTM, 
3 min, 3000 rpm), hydrated overnight and adjusted to pH 7. 
 
2.3. Rheological assessment of gels 
Continuous flow rheological assessment of the gels was performed using a TA Instruments AR 
1500 Rheometer (T.A. Instruments, Surrey, England) fitted with a 40 mm diameter stainless steel 
parallel plate assembly. Each gel sample was applied to the rheometer base plate, the upper plate 
lowered to a gap depth of 1000 μm, and excess gel removed before initiating the test. 
Experiments were conducted at 37 ± 0.1℃ in continuous ramp mode with the shear stress 
increased from 0 to 200 Pa over 10 min (40 sampling points) while shear rate measurements were 
recorded. Gel viscosities and power law indices (n) were determined by applying the Power Law 
to the linear portion of the resulting log-log plot of viscosity against shear rate.44 Four replicates 
were assessed for each formulation. 
  
2.4. In vitro release of maraviroc and emtricitabine from silicone gels 
SEG and h-SEG placebo gel compositions having a viscosity of 50 Pa.S were selected from the 
viscosity-composition plots. Active gels containing 5% w/w micronized maraviroc or 
emtricitabine were then prepared and assessed for in vitro release over 24 h using both simulated 
vaginal fluid (SVF)45 and isopropyl alcohol (IPA) / water (1:1 ratio) solutions as release media. 
Gel samples (1.0 g) were syringed into sealed plastic flasks containing 20 mL of release medium 
and the flasks placed in a shaking orbital incubator (Analab, Infors AGCH-4103, Bottmingen, 
Switzerland, 37oC, 60 rpm). Four replicates were assessed for each gel formulation. The release 
medium was sampled with volume replacement (1 mL) at 1, 2, 4, 6, 8 and 24 h. Maraviroc and 
emtricitabine concentrations were quantified by HPLC using a Waters Alliance e2695 HPLC 
(Waters, Dublin, Ireland) installed with Empower data handling software and connected to a 
Waters UV (2489) detector. A Phenomenex® Luna 5μ C18 (2) 100A 150 x 4.6 mm column was 
used for both compounds. For maraviroc, the mobile phase for the gradient flow method 
comprised 0.1% v/v trifluoroacetic acid (TFA) solution (A) and acetonitrile (B) at a flow rate of 1 
mL/min; 70% A 0-4.0 min, 20% A 4.0-4.5 min, 70% A 4.5-7.0 min. An isocratic flow method 
involving 80% water and 20% methanol was used to quantify emtricitabine. Maraviroc and 
emtricitabine were detected at 210 nm and 301 nm, respectively with retention times of 3.0 min 
and 4.0 min, respectively (based on 10 µL sample injections). 
 
2.5. Solubility determination of maraviroc and emtricitabine in cyclomethicone and 
st-PDMS  
The solubilities of maraviroc and emtricitabine in cyclomethicone and the various low molecular 
weight st-PDMSs (DMS S12, DMS S14, DMS S15, DMS S21) were determined by a shake flask 
method. Briefly, each drug was added to 5 mL of each solvent in sealed glass vials (n = 4) to 
form saturated suspensions. The vials were placed in a shaking orbital incubator (37 ºC, 60 rpm) 
for 5 days, then removed and equilibrated at room temperature (18 ± 1 oC, 24 h). The suspensions 
were filtered (MilliporeTM Millex-GS 0.22 µm syringe filters, Cork, Ireland), the filtrates (1 mL) 
added to methanol (5 mL), and the solution then analysed for maraviroc and emtricitabine content 
using the previously described HPLC methods.  
 
2.6. Aqueous dye ingression studies  
The relative hydrophilic character of the gels was assessed by ingression of aqueous methylene 
blue solution (0.01% w/v). Each silicone gel sample (3 g) was syringed into a glass vial and 
allowed to settle under gravity overnight. Methylene blue solution (5 mL) was pipetted on top of 
the gel sample, the glass vial sealed and placed in a shaking orbital incubator (37 ºC, 60 rpm), 
and the extent of dye ingression observed at 0, 6, 24 and 48 h. 
 
2.7. In vitro gel dilution 
In vivo dilution of the gels was modelled rheologically. Test samples of the SEG and h-SEGs (5 
g) were placed into plastic containers containing SVF (5 mL) (n=4). The containers were sealed 
and placed in an orbital shaking incubator (37 ºC, 60 rpm). At various time points (0, 6, 24 and 
48 h), excess SVF was removed, the remaining gel sample speed-mixed (3000 rpm, 1 min), and 
rheological flow analysis performed to determine gel viscosity.  
 
2.8. Effect of gels on the pH of SVF  
Three silicone gel formulations (80/20 SEG, DMS S12 h-SEG and DMS S52 h-SEG), 
representing the unmodified and the most and least hydrophilic modified silicone gels, 
respectively, were tested for their potential to modify the pH of SVF (pH = 4.2). SVF medium is 
specifically formulated to model the pH, osmolarity and minimal buffer capacity observed with 
native vaginal fluid.45 Gel samples (5.00 g) were placed in individual glass vials and SVF added 
(5.0 mL). The pH of the SVF phase was measured at 0, 1, 2, 4, 8 and 24 h.  
 
2.9. MTT assay of gel cytotoxicity 
Dulbecco’s Modified Eagle Medium (DMEM) supplemented with penicillin and streptomycin (5 
mL) was added to polypropylene sample bottles containing either no gel (control), HEC, SEG or 
DMS S12 h-SEG gels and incubated at 37°C for 5 days without agitation. TZM-bl cells were 
plated at a concentration of 2x104 cells/well in a 96 well format and allowed to form an adherent 
monolayer overnight. The following day, the media were removed from the gels and 
supplemented with 10% foetal calf serum and 1% L-glutamine. 200 μL of media was added to 
each well of cells.  Controls included fresh DMEM, 5 day old DMEM and 100 μg/mL 
nonoxynol-9 as a measure of complete cytotoxicity.  The plate was incubated for 24 h at 37 °C. 
The media were then removed from the cells and replaced with 200 μL/well of fresh DMEM 
containing 0.5 mg/mL MTT.  The plate was incubated for 2 h then MTT removed and cells lysed 
with 98% isopropanol and 2% 1N HCl. After thorough resuspension, absorbance was read at 570 
nm with background at 630 nm. 
 
2.9. Statistical analysis 
Statistical analysis was performed using GraphPad Prism software. Data were analyzed using 
either one or two-way ANOVA, depending on the number of variables to be compared. 
Significance was noted when p < 0.05. 
 
3. RESULTS 
3.1. Rheological assessment of gels  
All the h-SEGs displayed shear-thinning (i.e. pseudoplastic) behaviour, whereby viscosity 
decreased with increasing shear rate. Representative viscosity vs. shear rate rheograms for DMS 
S12 and DMS S51 h-SEGs with various concentrations of the DMS component are presented in 
Figure 2. h-SEGs prepared with the other st-PDMS components showed similar rheological 
properties. Comparative rheograms for the 80/20 SEG and 2.2% w/w HEC gel (250 HX grade) 
are also presented in Figure 2A. Apparent viscosity values for the 80/20 SEG and each of the h-
SEGs and HEC gels were determined from the gradient of the linear portions of the log-log plots 
of shear rate vs. viscosity (Power Law equation) and are plotted as a function of the percentage 
ST-Elastomer 10 and HEC concentrations in Figures 3A and 3B, respectively. The apparent 
viscosities of the SEGs and h-SEGs decreased significantly as the ST-Elastomer 10 component 
decreased (Fig. 3A), demonstrating the diluent nature of the cyclomethicone / DMS components. 
All the gels had power law index values of less than one, indicative of strongly shear-thinning 
behavior (data not presented). 
 
Small changes in the st-PDMS concentration within the h-SEG formulations caused very 
significant decreases in gel viscosity. Surprisingly, this concentration-dependent decrease in 
viscosity was more marked with the higher molecular weight st-PDMS systems. For example, the 
addition of 5% w/w DMS S51 produced a very significant decrease in viscosity (measured at a 
shear rate of 1 s-1) from 277 Pa.S (100% ST-Elastomer 10) to 19.5 Pa.S (95% ST-Elastomer 10). 
Similar dramatic decreases in viscosity were observed with the DMS S27 and DMS S35 h-SEGs 
(Fig. 3A). By comparison, the DMS S12 h-SEG, prepared with the lowest molecular weight 
DMS component (and therefore having the greatest percentage of hydroxyl groups), showed a 
less dramatic decrease in viscosity with increasing DMS S12 concentration; at 5% and 10% w/w 
DMS S12 contents, the gel viscosity had declined to 178 and 69 Pa.S, respectively. This 
unexpected result effectively permits a relatively hydrophilic h-SEG formulation to be prepared 
while maintaining gel viscosity within a range deemed appropriate for vaginal application (see 
following section for details). 
 
HEC gel viscosity was significantly influenced by both the HEC grade (molecular weight) and 
concentration (Fig. 3B). Gels prepared with the HX and HXX grades produced very similar 
viscosity profiles, ranging from 9 Pa.S at 1% w/w to 618 Pa.S at 5% w/w. The M-Pharm grade 
material produced lower viscosity gels (14 to 176 Pa.S). By comparison, the viscosities of five 
commercially available aqueous vaginal gels (Metrogel®, Gygel®, Replens®, Gynofit® and 
RepHresh®) were also measured (Fig. 3C), with viscosity values ranging from 33 Pa.S (Gynofit®) 
to 166 Pa.S (RepHresh®). The 80/20 SEG (Fig. 3A) and the 2.2% w/w HEC HX gel (Fig. 3B) 
had viscosity values close to 50 Pa.S, which falls within the range measured for the commercial 
products. h-SEG compositions with similar viscosity values are presented in Table 1. All 
viscosity values quoted were obtained at a shear rate of 1 s-1. Viscosity-matched gel formulations 
were next used for maraviroc and emtricitabine release testing in vitro. 
 
3.2 . In vitro release of maraviroc and emtricitabine from gels 
In vitro maraviroc release profiles into SVF and IPA/water are presented in Figures 4A and 4B 
for the 80/20 SEG, the DMS S12, DMS S21, DMS S27, DMS S35 and DMS S51 h-SEGs and the 
2.2% w/w HEC gel, each loaded with 5% w/w maraviroc. For both media, release was greatest 
for the HEC gel, with 51 mg released into IPA/water and 55 mg released into SVF after 24 h 
(equivalent to ~100% release). By comparison, the maximum cumulative release from a silicone 
gel was 18 mg (36%) (SVF) and 21 mg (42%) (IPA/water) for DMS S12 h-SEG (the silicone gel 
formulation containing the greatest percentage of silanol groups), reflecting the fact that the h-
SEGs are not aqueous miscible.  Significantly more maraviroc was released into both media for 
the DMS S12 and DMS S21 h-SEGs than for the 80/20 SEG. In SVF media, the DMS S12 and 
DMS S21 h-SEGs released 18 mg (36%) and 16 mg (31%) respectively after 24 h, compared to 
only 3 mg (7%) released from the 80/20 SEG. After 24 h in IPA/water, the DMS S12 and DMS 
S21 h-SEGs released 21 mg (42%) and 16 mg (31%), respectively, while 12 mg (24%) was 
released from the 80/20 SEG. The release of maraviroc from the DMS S27, DMS S35 and DMS 
S51 h-SEGs into both media was comparable to the 80/20 SEG after 24 h. 
 
In vitro release profiles for emtricitabine (5% w/w loading) are presented in Figures 4C and 4D 
for the various SEG, h-SEG and HEC gels into SVF and IPA/water, respectively. Once again, 
emtricitabine release was greatest for the HEC gel in both media, with 43 mg (86%) released into 
SVF and 45 mg (90%) into IPA/water, respectively. Emtricitabine release after 24 h from the 
DMS S12 (3.9 mg, 7.8%), DMS S21 (3.2 mg, 6.3%), DMS S27 (3.2 mg, 6.4%) and DMS S35 h-
SEGs (3.3 mg, 6.6%) was significantly greater than from the 80/20 SEG (2.4 mg, 5.6%) in SVF.  
The release of emtricitabine from the DMS S51 h-SEG (2.2 mg, 4.5%) after 24 h was comparable 
to the 80/20 SEG in SVF. After 24 h in IPA/water, only the release of emtricitabine from the 
DMS S12 h-SEG (14 mg, 28%) was significantly greater than from the 80/20 SEG (8.8 mg, 
18%). For the 80/20 SEG and DMS S21, S27, S35 and S51 h-SEGs, no significant differences in 
release into IPA/ water were observed (Figure 4D).  
 
3.3. Solubility of maraviroc and emtricitabine in st-PDMS and cyclomethicone 
No numerical value for the solubility of maraviroc and emtricitabine in cyclomethicone could be 
determined as concentrations were below the limit of detections for both HPLC methods 
(maraviroc – 5.0 μg/mL, emtricitabine - 1.1 μg/mL). The solubilities of maraviroc and 
emtricitabine in the various st-PDMS materials were measurable, and increased in proportion to 
the weight percentage of hydroxyl groups (Fig. 5). It was also noted that the solubility of 
maraviroc in the st-PDMS was up to 100-fold greater than emtricitabine when the percentage 
hydroxyl group values were comparable. For example, the solubility of maraviroc in DMS S12 
was 60 mg/mL whereas the emtricitabine solubility was only 0.46 mg/mL.  
 
3.4. Aqueous dye ingression analysis of SEGs and h-SEGs 
Ingression of methylene blue dye into the 80/20 SEG and the DMS S51 h-SEG (97.5/2.5) was not 
observed over 48 h (Fig. 6), reflecting the highly hydrophobic character of these gels. DMS S51 
is the most hydrophobic of the st-PDMS materials, having the lowest weight percentage of 
silanol groups. By contrast, ingression of methylene blue dye was very apparent for the relatively 
hydrophilic DMS S12 h-SEG (89/11) at 6 h (Fig. 6F); by 48 h, the dye had diffused throughout 
the entire gel sample (Fig. 6H). However, the gel layer and dye solution remained as two 
immiscible phases. 
 
3.5. In vitro gel dilution 
The viscosities of the 80/20 SEG, DMS S12 h-SEG and DMS S51 h-SEG gels decreased by a 
relatively small 10 – 20% after 48 h placement in SVF. Initial viscosities were 43, 53 and 49 
Pa.S, respectively, and final viscosities were 39, 43 and 42 Pa.S, respectively (Fig. 7). The latter 
three values were not significantly different from each other. By contrast, the initial viscosity of 
the 2.2% HEC (HX grade) gel was 61 Pa.S, but at 6 h it was too low to be measured using the 
rheological method due to its complete dilution in SVF. 
 
3.6. Influence of gels on pH of simulated vaginal fluid 
The pH of SVF was not significantly modified by the addition of SEG, DMS S12 h-SEG or DMS 
S52 h-SEG, with pH values maintained within the range 4.1 – 4.3 over a 24 h period (Fig. 8) and 
no significant differences observed between the gel formulations.  
 
3.7. Gel cytotoxicity 
Results are presented as raw optical density (OD) values then as a percentage of ODs obtained 
for the 5 day DMEM control. The results showed minimal difference between the 5-day media 
control and the fresh media control. The viability recorded for cells exposed to HEC gel plus 
media was 10.9% ± 6.6%. Cells exposed to media incubated with hSEG gel demonstrated 
viability of 24.6% ± 5.7%. Cells exposed to media incubated with SEG gel demonstrated viability 
of 108% ± 14%. Percentage viability values above 100% are considered to be an artefact of the 
analysis method and should be considered completely viable. 
 
4. DISCUSSION 
Aqueous gels based on polyacrylic acid (Carbopol®) and HEC have been studied extensively as 
vaginal delivery systems for HIV-1 microbicides.10,11,13-15,17,28,46-48 In fact, a HEC-based gel 
formulation has been developed as a ‘universal placebo’ for use in clinical trials of vaginal HIV 
microbicide gels.49 The greatest advantages associated with use of aqueous HEC-based vaginal 
gels include good safety data, ease of manufacture and low cost. Some surveys have reported that 
women tend to favour use of gels over other vaginal products due to their convenience and ease 
of insertion.49-52 Gels are also versatile and easily manipulated to achieve optimum performance 
and efficacy. 
 
Gel viscosity, which is largely influenced by gel composition, is one of the key determinants in 
the efficacy of vaginally administered pharmaceutical gels.53-56 For example, viscosity affects 
vaginal distribution and retention; lower viscosity gels tend to distribute more rapidly but are also 
more likely to be poorly retained.55-57 After application, aqueous gels are subjected to both high 
shear rates (related to the user’s physical activity) and the diluting effects of vaginal fluid.36,55 For 
these reasons, aqueous-based HIV microbicide gels are generally intended for administration 
immediately prior to sexual intercourse, so as to maximize local drug levels and increase 
efficacy.17,58 A major challenge remains for the development of vaginal gel formulations that can 
provide rapid and complete coverage of the tissue surfaces while also being retained for up to 24 
h to permit once-daily application.59 
 
Few studies have reported the effect of vaginal gel viscosity on retention and/or clinical efficacy. 
For HIV microbicide application, it is essential that the gel be distributed rapidly and widely 
throughout the vaginal cavity so as to form a protective physical barrier against transmission of 
virus and to deliver effective quantities of the constituent ARV(s) to the underlying tissue. A 
higher gel viscosity with poor spreadability characteristics has been linked to an increased risk of 
HIV-1 infection in hu-SCID mice.60 The universal placebo gel commonly used in microbicide 
trials contains 2.7% w/w HEC (HX grade) and has a viscosity of 68 Pa.S.49 A 2.2% w/w HEC gel 
used for vaginal delivery of maraviroc to rhesus macaques was determined to have a viscosity of 
44 Pa.S (at a shear rate of 1 s-1).28 The 80/20 SEG gel evaluated in this study (48 Pa.S) has also 
been tested in rhesus macaques.40 To facilitate comparisons of in vitro release of model ARV 
microbicides across SEG, h-SEG and HEC gel formulations, it was important that gels had 
similar viscosity values, since viscosity differences were also likely to influence release. Based 
on rheological testing of the 2.2% w/w HEC gel and the 80/20 SEG, we selected h-SEG gel 
compositions with viscosities of ~50 Pa.S to use for in in vitro release testing (Table 1), a value 
within the range of the five commercial vaginal gel products we also tested (Fig. 3).  
 
Hydrophobic silicone gels may overcome the poor vaginal retention observed with conventional 
aqueous gels by forming a non-dissolvable physical barrier layer at the vaginal mucosa. In a 
recent study, we found better in vitro retention and improved pharmacokinetics in rhesus 
macaques following a single dose vaginal application of maraviroc in a SEG 80/20 compared 
with a HEC-based gel.40 We hypothesized that partly or fully substituting the hydrophobic 
cyclomethicone component of a SEG with a relatively hydrophilic, low molecular weight, st-
PDMS (to form an h-SEG) might increase the release of the incorporated ARV while maintaining 
the site retention characteristics. The rationale was that the solubility of the ARV in the gel 
system would be improved without compromising the other advantageous properties of SEGs. As 
predicted, increased solubility of maraviroc and emtricitabine in the st-PDMS materials was 
observed with increasing weight percentage of silanol groups (Fig. 5), leading to increased 
release rates (Fig. 4). This observation is in accordance with the Higuchi model which describes 
diffusion-controlled release polymer matrices containing dispersed drugs.61,62 In fact, the general 
trend in in vitro release as a function of DMS type in the h-SEGs (Fig. 4) mirrors the solubility 
data for maraviroc and emtricitabine in the DMS compounds (Fig. 5).  
 
In vitro release of maraviroc and emtricitabine was greatest for the 2.2% w/w HEC gels, 
irrespective of the release medium used (Fig. 4). In fact, 100% drug release was achieved, 
consistent with a rapid breakdown in gel structure and complete dissolution of the drug. While 
such rapid drug release might be advantageous in providing high levels in vivo, it actually 
mitigates against a coitally independent microbicide gel product, since the drug release is 
unlikely to be sustained in vivo over more than a few hours at best. This supposition is consistent 
with results from a previous macaque study where the degree of protection afforded by a 
maraviroc HEC gel steadily declined from 86% to 0% as the interval between vaginal gel 
application and subsequent vaginal challenge was extended from 30 min to 12 h.28 A subsequent 
pharmacokinetic study testing the same maraviroc gel formulations provided additional insights 
into how the measured in vivo maraviroc concentrations (vaginal fluid, vaginal tissue, and 
plasma) correlated with the extent of protection.63 In that study, we noted that vaginal maraviroc 
concentrations typically declined by an order of magnitude over a 24 h period, presumably due in 
part to dilution and loss of the aqueous gel. 
 
Release of maraviroc from the DMS S12 h-SEG into SVF was four times greater than for 
emtricitabine after 24 h (Fig. 4), despite emtricitabine having a much greater aqueous solubility 
(100 mg/mL vs. 1 mg/mL for maraviroc). This discrepancy is directly attributable to the 
solubility difference of the two ARVs in DMS S12 PDMS; maraviroc was 100-fold more soluble 
(Fig. 6), reaffirming the importance of drug solubility in the polymeric matrix when optimizing 
its release from a delivery system.  However, drug solubility was not the only factor contributing 
to the enhanced release of maraviroc and emtricitabine from the DMS S12 h-SEG formulation. 
The increased hydrophilicity of the DMS S12 h-SEG (relative to the SEG 80/20 and the other 
DMS gels) facilitated the ingress of the aqueous release media into the gel matrix (Fig. 6), similar 
to that observed with the HEC gels. The ingress of fluid increases the surface area available for 
drug release and disrupts the gel matrix, although not to the extent that the rheological 
performance were greatly compromised (Fig. 7). For example, the final viscosity of the DMS S12 
h-SEG was not significantly different from those of the 80/20 SEG and DMS S51 h-SEG, 
indicating that rheological structure is maintained. By comparison, the rheological properties of 
aqueous HEC gels were compromised shortly after vaginal administration due to dilution by 
vaginal fluids.32,55,64 At 0 h, the viscosities of the 2.2% w/w HEC and DMS S12 h-SEG were 
similar (~50 Pa.S), but by the 6 h time-point the HEC gel had been diluted to such an extent that 
its viscosity was too low to be measured using the rheological technique. This outcome has major 
implications for in vivo retention. The advantage of the DMS S12 h-SEG is that ARV release 
from this system can be enhanced while maintaining rheological structure. Taken together, these 
two properties may provide optimized drug coverage and retention within the vagina.  
 
We used an established MMT cytotoxicity assay to measure and compare the toxicity of the new 
gel formulations with the widely used HEC-based vaginal placebo gel. Surprisingly, the HEC gel 
displayed the greatest toxicity. The h-SEG also displayed some cytotoxicity, though less than that 
seen with the HEC gel, while the SEG was free from negative effects. Unlike the SEG and the h-
SEG gels, the HEC gel dissolved in the DMEM, helping explain why this well-established and 
safe gel formulation showed an apparently high measure of cytotoxicity. The lack of aqueous 
solubility of the SEG and h-SEG gels contributed to their low cytotoxicity measurements. Using 
a slug mucosal irritation model, we have previously shown that the SEG and hSEG gels do not 
cause mucosal irritation.40 Compared to the HEC gel, the SEG and hSEG gels performed well. 
Considered in conjunction with their lack of toxicity in the slug mucosal irritation model, these 
results suggest that they are relatively non-toxic. However, the apparent toxicity of the HEC gel 
suggests that this assay may not be the most suitable for assessing formulation toxicity and 
further testing would be required to definitively establish formulation safety. 
 
CONCLUSIONS  
The study describes a novel, non-aqueous, semi-solid drug delivery system for the sustained 
release of small molecule ARVs after vaginal delivery. In particular, the hydrophilically modified 
silicone elastomer gels offer certain advantages over both aqueous HEC-based gels and standard 
silicone elastomer gels. They have considerable potential for development as a vaginally 
administered, once-daily, coitally independent microbicide product for prevention of HIV-1 
transmission. In vivo studies, both in relevant animal models and women, are required to assess 
the safety, drug pharmacokinetics and efficacy of these gels.      
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FIGURE CAPTIONS 
 
Figure 1. Chemical structures of silanol-terminated polydimethylsiloxane (st-PDMS), 
cyclomethicone, ST Elastomer 10, the nucleoside reverse transcriptase inhibitor emtricitabine and 
the HIV-1 entry inhibitor maraviroc. 
 
Figure 2. Representative flow rheograms for h-SEGs prepared from (A) DMS S12 and (B) DMS 
S51. Data for SEG 80/20 and HEC 250 HX control gels are also presented in A.   
 
Figure 3. Viscosities (Pa.S) of (A) placebo SEGs and h-SEGs having different ST-Elastomer 10 / 
cyclomethicone and ST-Elastomer 10 / st-PDMS ratios, and (B) placebo HEC gels having 
different HEC concentrations. The viscosities of five commercially available vaginal gels are 
presented in C. 
 
Figure 4. In vitro mean cumulative release versus time plots for maraviroc and emtricitabine 
from 80/20 SEG, DMS S12, DMS S21, DMS S27, DMS S35 and DMS S51 h-SEGs and the 
2.2% w/w HEC gel into SVF (A) and IPA/ water (1:1) (B) over 24 h (n=4) 
 
Figure 5. Solubility of maraviroc and emtricitabine in st-DMS S12 (6% hydroxyl groups), DMS 
S14 (3.5% hydroxyl groups), DMS S15 (1.05% hydroxyl groups) and DMS S21 (0.85% hydroxyl 
groups). Solubility was also assessed in cyclomethicone (0% hydroxyl groups), although values 
were below the limit of HPLC quantification. 
 
Figure 6. Ingression of aqueous methylene blue solution (blue top layer) into silicone elastomer 
gels (bottom layer). Bottom layer in photographs A–D comprise either SEG (80/20) (left vial in 
each photo) or DMS S51 h-SEG (97.5/2.5) (right vial in each photo) after 0 h (A), 6 h (B), 24 h 
(C) and 48 h (D). Photographs E–H show ingression into SEG (80/20) (left vial) and DMS S12 h-
SEG (89/11) (right vial) at the same time points. The main point to note here is that the aqueous 
methylene blue solution only ingresses into the relatively hydrophilic DMS S12 gel.   
 
Figure 7. Viscosity of placebo SEG, DMS S12 h-SEG and DMS S51 h-SEG expressed as a 
percentage of initial viscosity following dilution with SVF at 0, 6, 24 and 48 h. A 2.2% w/w HEC 
gel was also tested, but the viscosity had declined to non-measurable values by 6 h. 
 Figure 8. Influence of silicone gel formulation on pH of simulated vaginal fluid.  
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S14 (3.5% hydroxyl groups), DMS S15 (1.05% hydroxyl groups) and DMS S21 (0.85% hydroxyl 
groups). Solubility was also assessed in cyclomethicone (0% hydroxyl groups), although values 
were below the limit of HPLC quantification.  
     
 
    
 
Figure 6. Ingression of aqueous methylene blue solution (blue top layer) into silicone elastomer 
gels (bottom layer). Bottom layer in photographs A–D comprise either SEG (80/20) (left vial in 
each photo) or DMS S51 h-SEG (97.5/2.5) (right vial in each photo) after 0 h (A), 6 h (B), 24 h 
(C) and 48 h (D). Photographs E–H show ingression into SEG (80/20) (left vial) and DMS S12 h-
SEG (89/11) (right vial) at the same time points. The main point to note here is that the aqueous 
methylene blue solution only ingresses into the relatively hydrophilic DMS S12 gel.    
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 Figure 7. Viscosity of placebo SEG, DMS S12 h-SEG and DMS S51 h-SEG expressed as a 
percentage of initial viscosity following dilution with SVF at 0, 6, 24 and 48 h. A 2.2% w/w HEC 
gel was also tested, but the viscosity had declined to non-measurable values by 6 h.  
 Figure 8. Influence of silicone gel formulation on pH of simulated vaginal fluid.
Table 1. Composition of h-SEGs that produced a viscosity equivalent to the 80/20 conventional 
SEG and 2.2% w/w HEC (HX) gel (~50 Pa.S) used for in vitro release testing. 
Formulation Composition Viscosity (Pa.S) 
SEG 80/20 48.49 ± 4.87 
DMS S12 h-SEG 89/11 50.90 ± 1.20 
DMS S21 h-SEG 95/5 52.13 ± 3.33 
DMS S27 h-SEG 97.4/2.6 47.98 ± 1.98  
DMS S35 h-SEG 97.7/2.3 52.97 ± 2.90 
DMS S51 h-SEG 97.5/2.5 51.73 ± 0.89 
HEC (HX) 2.2 43.57 ± 1.03 
 
